The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Oncol.
Sec. Genitourinary Oncology
Volume 15 - 2025 |
doi: 10.3389/fonc.2025.1406585
This article is part of the Research Topic Advances in Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer View all 7 articles
Prognostic Evaluation of Non-muscle Invasive Bladder Cancer with P-CRP and Its Nomogram
Provisionally accepted
Wu Junyun 1
Zhixuan Deng 2
Xu Lei 3* Zhiyao Xu 4* Chenxi Tan 4* Yunqiao Tang 1* Xi Sheng 1* Ning Yang 1*- 1 Second Affiliated Hospital of University of South China, Hengyang, Hunan Province, China
- 2 Institute of Cell Biology,Hengyang Medical School,University of South China, Hengyang, Hunan Province, China
- 3 People's Hospital of Qianxinan Prefecture, Qianxinan, China
- 4 Hengyang Medical School, University of South China, Hengyang, Hunan Province, China
Purpose: To investigate the impact of the product of preoperative platelet count and C-reactive protein (P-CRP) on the postoperative prognosis of patients with non-muscle invasive bladder cancer (NMIBC), and to construct a Nomogram to predict the recurrencefree survival (RFS) of NMIBC patients based on pathological data. Methods:A retrospective analysis was conducted on the clinical data of 164 NMIBC patients who underwent transurethral resection of bladder tumors (TURBT) at the Second Affiliated Hospital of University of South China from January 2013 to December 2019. The endpoint of the study was the RFS. Kaplan-Meier (KM) method and Cox regression were used for analysis to identify independent factors affecting RFS. Then, the Nomogram was used to visualize the results of the multivariate analysis that were statistically significant and related to the RFS of NMIBC patients. Finally, the predictive ability of the model was evaluated using the concordance index (C-index) and calibration curves. Results: Before the end of the follow-up, the RFS was 88.3% at 1 year, 75.5% at 2 years, 31 and 58.5% at 3 years. KM curves showed that P-CRP (HR=0.357, 95% CI: 0.204-0.625, 32 P<0.001), number of tumors (HR=2.658, 95% CI: 1.572-4.494, P<0.001), tumor size 33 (HR=2.271, 95% CI: 1.377-3.745, P=0.001), T stage of the tumor (HR=2.026, 95% CI: 34 1.233-3.329, P=0.005), and tumor G grade (G2: HR=1.615, 95% CI: 0.48-5.433, G3: 35 HR=3.361, 95% CI: 1.022-11.054) were independent factors affecting the RFS of NMIBC 36 patients after TURBT. The Nomogram could estimate the risk of tumor recurrence at 1, 2, 37 and 3 years postoperatively. The Nomogram model incorporating P-CRP parameters had a 38 higher predictive accuracy than the classic model that only included EORTC risk group 39 parameters. 40 Conclusion: Preoperative P-CRP has a certain impact on the RFS of NMIBC patients after 41 TURBT. The Nomogram incorporating P-CRP, number of tumors, tumor size, T stage, and 42 tumor pathological grading can better predict the postoperative recurrence risk of NMIBC 43 patients. 44 Keywords: Non-muscle invasive bladder cancer; P-CRP; Prognostic analysis; Nomogram; 45 Recurrence-free survival
Keywords: Non-muscle invasive bladder cancer, P-CRP, prognostic analysis, nomogram, Recurrence-free survival
Received: 11 Apr 2024; Accepted: 14 Jan 2025.
Copyright: © 2025 Junyun, Deng, Lei, Xu, Tan, Tang, Sheng and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Xu Lei, People's Hospital of Qianxinan Prefecture, Qianxinan, China
Zhiyao Xu, Hengyang Medical School, University of South China, Hengyang, Hunan Province, China
Chenxi Tan, Hengyang Medical School, University of South China, Hengyang, Hunan Province, China
Yunqiao Tang, Second Affiliated Hospital of University of South China, Hengyang, Hunan Province, China
Xi Sheng, Second Affiliated Hospital of University of South China, Hengyang, Hunan Province, China
Ning Yang, Second Affiliated Hospital of University of South China, Hengyang, Hunan Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.